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Abstract
One of the holy grails of modern medicine, across a range of
clinical sub-specialties, is establishing highly sensitive and specific
biomarkers for various diseases. Significant success has been
achieved in some of these clinical areas, most notably identifying
high-sensitivity C-reactive peptide, troponin I/T and brain natriuretic
peptide as significant prognosticators for both the acute outcome
and the development of cardiovascular pathology. However, it is
highly debatable whether this translates to complex, multi-system
pathophysiological insults. Is critical care immune from the
application of these novel biomarkers, given the numerous con-
founding factors interfering with their interpretation?
In the previous issue of Critical Care [1], Fellahi and
colleagues, in a large observational study, describe troponin-I
release in three cohorts of cardiac surgical patients
undergoing bypass grafts, valve replacement(s) or both. They
report that patients undergoing both valve and bypass graft
procedures sustained more cardiac damage, but the
troponin-threshold for clinically significant events was higher
in these patients. There are no cardiac tissue samples or
serial echocardiographic data to provide histopathological
and/or physiologic corroboration of these findings. On face
value these results are perhaps not surprising, given that
intuitively greater cardiac tissue damage, longer bypass time
and hence a larger inflammatory stimulus would be predicted
for patients undergoing valvular replacement alone or the dual
procedure. Nevertheless, these are valuable data in that they
illustrate some of the complexities surrounding troponin, a
justifiably established star of the new biomarker age, in the
sphere of critical care. The limitations of troponin, including
the lack of universal measurement standards and its
interpretation in the critically ill patient have been discussed
in detail in this journal recently [2]. A key issue surrounding
the utility of troponin remains the mechanism(s) of myocardial
injury in both the cardiac surgical and critically ill patient
which, despite the high incidence reported in several critical
care studies over the last 10 years, continues to elude
workers in this field.
Unsurprisingly, other novel biomarkers that have strikingly
similar utility in specific patient populations (most notably
cardiac failure) have failed to evade the attention of critical
care clinical researchers. Recently, conflicting data have
emerged for brain natruretic peptide (BNP) in sepsis [3,4], an
otherwise excellent specific biomarker for the cardiac failure
population [5]. An often overlooked reason for this dichotomy
is the fundamentally altered pharmaco-physiology of the
critically ill patient. An elegant example is served by the
finding that lipopolysaccharide induces BNP expression
independently in a cultured cardiac myocyte model, free of
haemodynamic perturbations [6]. Thus, a significant
component of the elevation in BNP in septic patients may be
a consequence of invasive bacterial infections and/or gut-
derived endotoxin, both unrelated to primary haemodynamic
impairment. Other important triggers for BNP expression are
mediated through mitogen activated protein (MAP) kinase
pathways [7], including cytokines, beta and particularly alpha
adrenergic agonists [8]. These important laboratory findings
clearly highlight whether novel biomarkers like BNP and
troponin are merely demonstrating the sequelae of our
current treatment regimes for critically ill patients. Untangling
the relationship between primary pathology, its biomarkers
and the consequences of treatment/processes that drive that
biomarker expression further is a recurring hurdle that may
prove insurmountable. Nevertheless, the essential question
that many of the new wave of critical care biomarker studies
present is whether the results of these tests, assuming they
are specific and sensitive, would alter our management of the
critically ill patient fundamentally. So far, there have been no
interventional studies based on the measurement of such
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novel biomarkers in the general critically ill population. This
would seem a crucial step to justify the continued efforts in
defining what elevations of various biomarkers mean.
Furthermore, the combined number of patients studied in the
critical care biomarker literature is severalfold smaller than
those conducted in limited or single-organ, clearly defined,
often subtle/pre-clinical disease states, where tens of
thousands of patients have been recruited [9]. Importantly,
the utility (and basic scientific understanding) of many of
these novel biomarkers has been reinforced by predictable
changes in their levels upon specific, clinically relevant and
successful interventions [9,10]. Again, this is a major
challenge given the complexity, and relatively poor outcomes,
associated with the critically ill patient. Just as single
interventions have failed to alter outcomes in severe sepsis, it
seems highly unlikely that the measurement of biomarkers in
isolation from an associated “package of care” will alter
critical care outcomes. This serves to remind us of the
importance of large population clinical research in critical
care medicine and the dangers of extrapolating population-
centred, relatively uncomplicated, limited, single-organ patho-
physiology to the critically ill patient. However, defining
subsets of critical care patients to explore these hypotheses
may be fruitful. For example, elevated preoperative levels of
high sensitivity C-reactive peptide and BNP are associated
with poorer postoperative outcome, albeit in small studies
thus far [11,12]. Perhaps stratifying postoperative critical
care using these new biomarkers, well before complex
inflammatory and septic pathophysiological alterations
escalate, will become an important economic and clinical
contribution that further research can make.
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